Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?
Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (CLL) (i.e., refractory to purine analogs, short response (<24 months) to intensive treatments, and/or presence of 17p/TP53 abnorma...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
5 February 2015
|
| In: |
Current hematologic malignancy reports
Year: 2015, Volume: 10, Issue: 1, Pages: 59-64 |
| ISSN: | 1558-822X |
| DOI: | 10.1007/s11899-014-0242-1 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s11899-014-0242-1
|
| Author Notes: | Peter Dreger, Emili Montserrat, on behalf of the European Society for Blood and Marrow Transplantation (EBMT) and the European Research Initiative on CLL (ERIC) |
| Summary: | Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (CLL) (i.e., refractory to purine analogs, short response (<24 months) to intensive treatments, and/or presence of 17p/TP53 abnormalities). Currently, new and highly effective therapeutic agents targeting BCR-mediated intracellular signal transduction have been incorporated into the CLL treatment armamentarium. These signal transduction inhibitors (STI) will change the algorithms of high-risk CLL (HR-CLL) management. Despite the limited body of evidence, there is sufficient rationale for withholding alloHSCT in patients with 17p-/TP53mut CLL in first remission. In contrast, the perspectives of patients with relapsed 17p-/TP53mut CLL remain uncertain even if responding to STI. The same accounts for patients with HR-CLL progressing under STI. In both scenarios, it is reasonable to consider alloHSCT, ideally after response to alternative STI regimens. |
|---|---|
| Item Description: | Gesehen am 29.06.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1558-822X |
| DOI: | 10.1007/s11899-014-0242-1 |